Serious adverse events · healthy individuals and those with a pre‐existing health condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · daytime workers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children aged up to 16 years with ARTIs
Homeopathic medicinal products (individualised treatment) showed no clear difference in adverse events compared with placebo or usual care (moderate certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · children aged up to 16 years with ARTIs
It is very uncertain whether homeopathic medicinal products (non‐individualised treatment) changes adverse events compared with placebo or usual care (very low certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Adverse events ‐ incidents of unspecified severe adverse events · Adults with co‐morbid PTSD and SMI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ incidents of unspecified severe events ‐ medium term · Adults with co‐morbid PTSD and SMI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ incidents of unspecified severe adverse events ‐ medium term · Adults with co‐morbid PTSD and SMI
1 finding from 1 review
Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
An extended NVP plus ZDV dual regimen administered to infants for 14… may leads to higher infants with any Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).
1 finding from 1 review
Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
It is very uncertain whether an extended NVP plus ZDV dual regimen administered to infants for 14… changes infants with Probably Related Severe Adverse Events compared with an extended NVP regimen administered to infants (very low certainty).
1 finding from 1 review
Adverse events: most commonly occurring events (occurring in at least 10% of participants) · adults and children with cystic fibrosis
1 finding from 1 review
Adverse effects: 1. Sedation · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in individual adverse events ‐ Sedation At 3 weeks (secondary… compared with lithium (low certainty).
1 finding from 1 review
Adverse events: somnolence/sedation · Children and adolescents with acute mania
It is very uncertain whether valproate changes individual adverse events ‐ Sedation At 8 weeks (secondary… compared with lithium (very low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · Children and adolescents with acute mania
It is very uncertain whether valproate changes individual adverse events ‐ Sedation At 4 weeks (secondary… compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in individual adverse events ‐ Sedation At 3‐8 weeks (secondary… compared with placebo (high certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found